AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24060767 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution
Number of subjects: 30
Study 21875778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 13776
Study 21875778 — intervention group
Group type: COMPARATOR
Intervention: No Clopidogrel
Number of subjects: 13776
Study 20368852 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 78
Study 20368852 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazene (SSD) dressing
Number of subjects: 78
Study 18261358 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (yellow ligament dissected, sodium hyaluronate sprinkled)
Number of subjects: 165
Study 18261358 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (yellow ligament reserved)
Number of subjects: 165
Study 18261358 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (yellow ligament reserved, sodium hyaluronate sprinkled)
Number of subjects: 165
Study 15157690 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg.kg(‐1) body weight caffeine
Number of subjects: 12
Study 15157690 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg.kg(‐1) body weight caffeine
Number of subjects: 12
Study 15157690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11307042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 41-3696 at 10 mg
Number of subjects: 40
Study 11307042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 41-3696 at 3 mg
Number of subjects: 40
Study 11307042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 41-3696 at 5 mg
Number of subjects: 40
Study 11307042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 41-3696 at 1 mg
Number of subjects: 40
Study 11307042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9494145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg daily)
Number of subjects: 2539
Study 9494145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2539
Study 7805371 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene 75 mcg plus ethinyl estradiol 30 mcg
Number of subjects: 176
Study 7805371 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel 150 mcg plus ethinyl estradiol 30 mcg
Number of subjects: 176
Study 3280000 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CyA) at a mean dose of 5.5 mg/kg/day
Number of subjects: 20
Study 3280000 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CyA vehicle)
Number of subjects: 20
Study 3280000 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CyA) at a mean dose of 5.6 mg/kg/day
Number of subjects: 20
Study 3280000 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CyA) at a lower mean dose of 3 mg/kg/day during tapering off phase
Number of subjects: 20
Study 3280000 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA treatment
Number of subjects: 20
Study 31813283 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium Laser Enucleation of Prostate (HoLEP)
Number of subjects: 64
Study 31813283 — intervention group
Group type: COMPARATOR
Intervention: Bipolar Plasmakinetic Enucleation of Prostate (BPEP)
Number of subjects: 64
Study 29159975 — intervention group
Group type: EXPERIMENTAL
Intervention: RCAT (Rhinitis Control Assessment Test)
Number of subjects: 127
Study 28555959 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5 mg with eventual escalation to 25 mg daily over a 4-week period)
Number of subjects: 0
Study 28555959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28555959 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 25938157 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block combined with fixed appliance
Number of subjects: 31
Study 25938157 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliance after tooth extraction
Number of subjects: 31
Study 25938157 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Twin-block and fixed appliance
Number of subjects: 31
Study 24455542 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (66 Gy in 33 fractions, 5 fractions/week, with concomitant chemotherapy - Cisplatin 30 mg/m² IV once weekly for 6 weeks)
Number of subjects: 64
Study 24455542 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (66 Gy in 33 fractions, 6 fractions/week)
Number of subjects: 64
Study 24455542 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm C (30 Gy in 15 fractions followed by 1.4 Gy twice daily for 15 days, total 72 Gy in 6 weeks)
Number of subjects: 64
Study 21526444 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose transdermal nicotine (21/14 mg for men/women)
Number of subjects: 104
Study 21526444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 21526444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose transdermal nicotine (7 mg)
Number of subjects: 104
Study 21526444 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 104
Study 18442690 — intervention group
Group type: EXPERIMENTAL
Intervention: OrthoPilot navigation system (B. Braun‐Aesculap, Tuttlingen, Germany)
Number of subjects: 80
Study 18442690 — intervention group
Group type: COMPARATOR
Intervention: Standard manual targeting technique
Number of subjects: 80
Study 17133529 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS (anode over primary motor cortex)
Number of subjects: 32
Study 17133529 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study 12652326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg bolus plus a maintenance infusion)
Number of subjects: 24
Study 12652326 — intervention group
Group type: COMPARATOR
Intervention: Intravenous digoxin (13 mcg/kg)
Number of subjects: 24
Study 12652326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 24
Study 12652326 — intervention group
Group type: COMPARATOR
Intervention: Intravenous digoxin
Number of subjects: 24
Study 10751074 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly rifapentine + isoniazid (HRp1)
Number of subjects: 762
Study 10751074 — intervention group
Group type: EXPERIMENTAL
Intervention: HRp1 given in 2 of every 3 weeks (HRp1.2/3)
Number of subjects: 762
Study 10751074 — intervention group
Group type: COMPARATOR
Intervention: Three times weekly isoniazid + rifampicin (HR3)
Number of subjects: 762
Study 8609830 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant recombinant human growth hormone (rhGH) treatment (0.15 mg/kg/d)
Number of subjects: 20
Study 8609830 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of infusion (Control)
Number of subjects: 20
Study 1575820 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate 600 mg/day
Number of subjects: 83
Study 1575820 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 83
Study 4048364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular conditioning program
Number of subjects: 0
Study 4048364 — intervention group
Group type: COMPARATOR
Intervention: Control program (designed to give the appearance of physical training)
Number of subjects: 0
Study 30368981 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 215
Study 30368981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 215
Study 30368981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 30232699 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablet
Number of subjects: 0
Study 30232699 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol 5 mg Tablet and Amlodipine 5 mg Tablet (Control)
Number of subjects: 0
Study 27634471 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot Gym therapy (technology-assisted rehabilitation)
Number of subjects: 20
Study 27634471 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 20
Study 24658389 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoption of three/four healthy behaviors
Number of subjects: 867
Study 24658389 — intervention group
Group type: COMPARATOR
Intervention: No change in health behaviors
Number of subjects: 867
Study 22308241 — intervention group
Group type: EXPERIMENTAL
Intervention: COGRAT (Cognitive therapy + Graded activity training)
Number of subjects: 83
Study 22308241 — intervention group
Group type: COMPARATOR
Intervention: CO (Cognitive therapy only)
Number of subjects: 83
Study 22308241 — intervention group
Group type: EXPERIMENTAL
Intervention: COGRAT
Number of subjects: 83
Study 22308241 — intervention group
Group type: COMPARATOR
Intervention: CO
Number of subjects: 83
Study 20736151 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc + Optimized Background Therapy (OBT)
Number of subjects: 635
Study 20736151 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Optimized Background Therapy (OBT)
Number of subjects: 635
Study 17585116 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 2 days + midazolam (2.5 mg) (EM2)
Number of subjects: 12
Study 17585116 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 4 days + midazolam (2.5 mg) (EM4)
Number of subjects: 12
Study 17585116 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 7 days + midazolam (2.5 mg) (EM7)
Number of subjects: 12
Study 17585116 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (5 mg) without erythromycin (EM0)
Number of subjects: 12
Study 15693914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 230
Study 15693914 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of four probiotic strains (MIX)
Number of subjects: 230
Study 15693914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 12227708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day) for 6 months
Number of subjects: 24
Study 12227708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bezafibrate)
Number of subjects: 24
Study 10509849 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily for nonulcer patients, 20 mg twice daily for ulcer patients for 14 days) plus two antimicrobials (amoxicillin, clarithromycin or roxithromycin, metronidazole, ornidazole, or tinidazole for 10 days)
Number of subjects: 518
Study 7760866 — intervention group
Group type: EXPERIMENTAL
Intervention: Six weeks of oral anticoagulant therapy (warfarin or dicumarol)
Number of subjects: 902
Study 7760866 — intervention group
Group type: COMPARATOR
Intervention: Six months of oral anticoagulant therapy (warfarin or dicumarol)
Number of subjects: 902
Study 2179082 — intervention group
Group type: EXPERIMENTAL
Intervention: D,L-Kavain (Neuronika)
Number of subjects: 38
Study 2179082 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 38
Study 2179082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6780632 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 52
Study 31219504 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation
Number of subjects: 11
Study 31219504 — intervention group
Group type: COMPARATOR
Intervention: Deep brain stimulation switched off
Number of subjects: 11
Study 31219504 — intervention group
Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation during movement task
Number of subjects: 11
Study 27933512 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine treatment (Zuogui Pill and Yougui Pill for low risk; Qingwen Baidu Decoction and Bazhen Decoction for moderate risk; Gexia Zhuyu Decoction and Qinghao Biejia Decoction combined with Shiquan Dabu Decoction for high risk)
Number of subjects: 60
Study 27933512 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 60
Study 26015773 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief weight reduction intervention during routine consultations
Number of subjects: 50
Study 26015773 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 50
Study 22944725 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive P. aeruginosa serology (baseline)
Number of subjects: 0
Study 22944725 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity to alkaline protease
Number of subjects: 0
Study 22944725 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity to exotoxin A
Number of subjects: 0
Study 22944725 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline seropositivity
Number of subjects: 0
Study 21067823 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine hydrochloride (20 mg/ml) with 0.00125% epinephrine
Number of subjects: 60
Study 21067823 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% bupivacaine hydrochloride
Number of subjects: 60
Study 21067823 — intervention group
Group type: COMPARATOR
Intervention: Topical saline
Number of subjects: 60
Study 19846734 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone/bupropion (NB16)
Number of subjects: 419
Study 19846734 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone/bupropion (NB32)
Number of subjects: 419
Study 19846734 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone/bupropion (NB48)
Number of subjects: 419
Study 18154996 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical revascularization
Number of subjects: 376
Study 18154996 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization
Number of subjects: 376
Study 18154996 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 376
Study 15459217 — intervention group
Group type: EXPERIMENTAL
Intervention: R115777 (300 mg twice daily)
Number of subjects: 368
Study 15459217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 14510128 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine nursing care plus interrupted direct current (IDC) stimulations
Number of subjects: 7
Study 14510128 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care plus placebo IDC
Number of subjects: 7
Study 9540015 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention (decreasing calories and fat intake)
Number of subjects: 154
Study 9540015 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (goal of 1,500 kcal/week of moderate activity)
Number of subjects: 154
Study 9540015 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diet plus exercise
Number of subjects: 154
Study 9540015 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 154
Study 9540015 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (diet, exercise, combination)
Number of subjects: 154
Study 8210250 — intervention group
Group type: EXPERIMENTAL
Intervention: MST-16 at 1,600 mg/body for 5 consecutive days repeating every 4 weeks
Number of subjects: 28
Study 8210250 — intervention group
Group type: EXPERIMENTAL
Intervention: MST-16 at 1,200 mg/body for 10-14 consecutive days every 5 weeks
Number of subjects: 28
Study 8210250 — intervention group
Group type: EXPERIMENTAL
Intervention: MST-16 at 1,200 mg/body daily for at least 4 weeks
Number of subjects: 28
Study 8210250 — intervention group
Group type: EXPERIMENTAL
Intervention: MST-16 (all doses)
Number of subjects: 28
Study 2508457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine
Number of subjects: 20
Study 2508457 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroglycerin
Number of subjects: 20
Study 22216522 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg and 200 mg daily)
Number of subjects: 17
Study 22216522 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (200 mg and 400 mg daily)
Number of subjects: 17
Study 22216522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31511289 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasonography (CEUS)
Number of subjects: 42
Study 31511289 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional power Doppler (3DPD) angiography
Number of subjects: 42
Study 31511289 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS and 3DPD
Number of subjects: 42
Study 29061169 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) for 30 minutes
Number of subjects: 40
Study 29061169 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation for 30 minutes
Number of subjects: 40
Study 25398967 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus Vitamin D3 (1000 mg/d of calcium plus 400 IU/d of vitamin D3)
Number of subjects: 35983
Study 25398967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35983
Study 23514701 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP transdermal patch
Number of subjects: 0
Study 23514701 — intervention group
Group type: COMPARATOR
Intervention: TMP oral tablets (TMPP)
Number of subjects: 0
Study 21555034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 44
Study 21555034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20137710 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 140
Study 20137710 — intervention group
Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 140
Study 16924336 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive topical application of Carisolv + SRP
Number of subjects: 60
Study 16924336 — intervention group
Group type: EXPERIMENTAL
Intervention: Active topical application of Carisolv + SRP
Number of subjects: 60
Study 16924336 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple applications of Carisolv + SRP
Number of subjects: 60
Study 16924336 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 24% EDTA
Number of subjects: 60
Study 16924336 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 60
Study 16924336 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Carisolv + SRP + 24% EDTA
Number of subjects: 60
Study 14714579 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril (5‐10 mg/day) or benazepril (10‐20 mg/day) for 6 weeks
Number of subjects: 517
Study 10986059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy including multiple, prolonged courses of corticosteroid (dexamethasone)
Number of subjects: 1409
Study 10986059 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 21-day dexamethasone courses
Number of subjects: 1409
Study 10986059 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 10 to 20 years old
Number of subjects: 1409
Study 10986059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic groups
Number of subjects: 1409
Study 10986059 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ON diagnosis
Number of subjects: 1409
Study 10986059 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic procedures
Number of subjects: 1409
Study 10986059 — intervention group
Group type: COMPARATOR
Intervention: Event-free survival
Number of subjects: 1409
Study 9568323 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-8 levels in burned patients postburn
Number of subjects: 10
Study 9568323 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-8 levels in septic patients
Number of subjects: 10
Study 9568323 — intervention group
Group type: COMPARATOR
Intervention: Serum IL-8 levels in healthy laboratory personnel
Number of subjects: 10
Study 8396025 — intervention group
Group type: EXPERIMENTAL
Intervention: Quorn myco‐protein (high fibre)
Number of subjects: 18
Study 8396025 — intervention group
Group type: COMPARATOR
Intervention: Chicken (low-fibre)
Number of subjects: 18
Study 3534246 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment over 12 weeks (6-week standard trial followed by 6-week continuation for responders)
Number of subjects: 0
Study 3534246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31547949 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint therapy
Number of subjects: 45
Study 31547949 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint therapy with ultrasound‐guided arthrocentesis
Number of subjects: 45
Study 31547949 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint therapy with low‐level laser therapy
Number of subjects: 45
Study 29921302 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participation in antenatal care plus current routine care
Number of subjects: 14
Study 29921302 — intervention group
Group type: COMPARATOR
Intervention: Current routine care
Number of subjects: 14
Study 26600285 — intervention group
Group type: EXPERIMENTAL
Intervention: AHH intervention (community-based bilingual promotoras providing in-person or telephone patient engagement)
Number of subjects: 348
Study 26600285 — intervention group
Group type: COMPARATOR
Intervention: DHS PCMH team usual care (PCMHUC)
Number of subjects: 348
Study 23943291 — intervention group
Group type: EXPERIMENTAL
Intervention: Q1 (TTO instruction not emphasizing reduced life expectancy)
Number of subjects: 656
Study 23943291 — intervention group
Group type: COMPARATOR
Intervention: Q2 (TTO instruction emphasizing reduced life expectancy)
Number of subjects: 656
Study 23943291 — intervention group
Group type: EXPERIMENTAL
Intervention: Q1
Number of subjects: 656
Study 23943291 — intervention group
Group type: COMPARATOR
Intervention: Q2
Number of subjects: 656
Study 22588407 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia and femoral nerve block (PCEA/FNB)
Number of subjects: 90
Study 22588407 — intervention group
Group type: COMPARATOR
Intervention: Periarticular injection (PAI)
Number of subjects: 90
Study 20565314 — intervention group
Group type: EXPERIMENTAL
Intervention: Unit-dose pipettes
Number of subjects: 41
Study 20565314 — intervention group
Group type: COMPARATOR
Intervention: Conventional eye drop bottles
Number of subjects: 41
Study 18391094 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care treatment with chlorthalidone and atenolol (n=2365)
Number of subjects: 4736
Study 18391094 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=2371)
Number of subjects: 4736